Falcigo Plus Tablet (Artesunate/Mefloquine) is a prescription medication widely used for the treatment, prevention, and control of malaria, including severe and drug-resistant cases. It is especially effective against malaria caused by the Plasmodium falciparum parasite and is suitable for use in patients in the United States, the United Kingdom, and Canada. Manufactured by Zydus Cadila Pharma, Falcigo Plus combines two potent antimalarial agents—Artesunate and Mefloquine—to ensure effective parasite clearance and rapid symptom relief.
The active ingredients in Falcigo Plus work synergistically to combat malaria. Artesunate, a derivative of artemisinin, kills the parasite by producing toxic compounds in the blood that disrupt its lifecycle. Mefloquine complements this action by targeting parasites at different stages of growth, preventing further infection. Together, they provide a robust treatment for both uncomplicated and severe malaria, including strains resistant to chloroquine and quinine.
Falcigo Plus is administered orally in tablet form and can be taken with or without food, though maintaining a consistent dosing schedule is recommended. It is important to follow your physician’s instructions regarding dosage to maximize effectiveness and minimize the risk of side effects. If a dose is missed, take it as soon as possible unless it is near the time of the next scheduled dose; never double up on doses.
Common side effects may include nausea, vomiting, dizziness, headache, diarrhea, skin rash, visual disturbances, and unusual tiredness. More serious side effects are rare but require immediate medical attention. Patients with liver disease, pregnant women, or breastfeeding mothers should consult their healthcare provider before using Falcigo Plus, as dose adjustments or alternative therapies may be necessary.
Falcigo Plus Tablet provides fast and effective relief from malaria, helping to control symptoms, prevent complications, and improve overall health outcomes. Available for online purchase, it offers convenient delivery to patients in the USA, UK, Canada, and other regions, ensuring timely access to this essential antimalarial treatment.